BIOHAVEN LTD (BHVN) Stock Overview
USA - NYSE:BHVN - VGG1110E1079 - Common Stock
BHVN Key Statistics, Chart & Performance
The current stock price of BHVN is 17.39 USD. In the past month the price increased by 18.62%. In the past year, price decreased by -65.82%.
BHVN Latest News, Press Relases and Analysis
BHVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.83B | ||
| AMGN | AMGEN INC | 13.35 | 156.75B | ||
| GILD | GILEAD SCIENCES INC | 15.56 | 149.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 107.73B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 62.04B | ||
| ARGX | ARGENX SE - ADR | 90.1 | 51.09B | ||
| INSM | INSMED INC | N/A | 34.67B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.08 | 34.65B | ||
| NTRA | NATERA INC | N/A | 26.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.49B | ||
| BIIB | BIOGEN INC | 9.4 | 22.05B |
Related stock screener links
About BHVN
Company Profile
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 256 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Company Info
BIOHAVEN LTD
215 Church Street
New Haven CONNECTICUT 06510 US
CEO: Vlad Coric
Employees: 256
Phone: 12034040410
BIOHAVEN LTD / BHVN FAQ
What does BHVN do?
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 256 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
What is the current price of BHVN stock?
The current stock price of BHVN is 17.39 USD. The price increased by 4.76% in the last trading session.
Does BHVN stock pay dividends?
BHVN does not pay a dividend.
What is the ChartMill rating of BIOHAVEN LTD stock?
BHVN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of BIOHAVEN LTD (BHVN) based on its PE ratio?
BIOHAVEN LTD (BHVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.66).
Is BIOHAVEN LTD (BHVN) expected to grow?
The Revenue of BIOHAVEN LTD (BHVN) is expected to decline by -31.41% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is BIOHAVEN LTD worth?
BIOHAVEN LTD (BHVN) has a market capitalization of 1.84B USD. This makes BHVN a Small Cap stock.
BHVN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BHVN. When comparing the yearly performance of all stocks, BHVN is a bad performer in the overall market: 91.35% of all stocks are doing better.
BHVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BHVN. BHVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
BHVN Financial Highlights
Over the last trailing twelve months BHVN reported a non-GAAP Earnings per Share(EPS) of -7.66. The EPS increased by 16.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -139.34% | ||
| ROE | -569.87% | ||
| Debt/Equity | 0 |
BHVN Forecast & Estimates
24 analysts have analysed BHVN and the average price target is 47.19 USD. This implies a price increase of 171.37% is expected in the next year compared to the current price of 17.39.
For the next year, analysts expect an EPS growth of 15.79% and a revenue growth -31.41% for BHVN